secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001564590-21-056202
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q3 net loss $60.8M; cash + offering totals ~$1B, runway into 2025
--------------------------------------------------------------------------------

- Net loss $60.8M ($0.66/share) vs $36.1M ($3.00/share) Q3 2020; R&D expenses nearly doubled to $45.0M.
- Cash, equivalents, investments $616.5M at Sept 30, plus $402M net from follow-on offering, providing runway at least into 2025.
- RLY-4008 interim data show selective FGFR2 inhibition; co to select RP2D and start expansion cohorts by end of 2021.
- RLY-2608 preclinical data support it as first allosteric pan-mutant selective PI3Kα inhibitor; combination data at SABCS Dec 2021.
- Follow-on public offering raised $402M gross proceeds, completed after quarter end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000156459021056202/0001564590-21-056202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000156459021056202/rlay-8k_20211110.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-056202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer